IMI2 - Call 16

IMI2 – Call 16 was launched on 18 July 2018 with the following topics:

  • Progress new assets (one pre-new molecular entity (preNME) and one first-time-in-human (FTIH) start) for tuberculosis (TB) that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors
  • Progress novel assets (one FTIH start) for non-tubercular mycobacteria (NTM) that may act synergistically with bedaquiline and cytochrome bc drugs
  • Discover and progress novel assets with new mechanisms of action (one preNME for TB and one preNME for NTM) and biomarkers for TB and NTM infection
  • Determination of gepotidacin levels in tonsils and prostatic tissue
  • Infection site targeting, antibiotic encapsulated in nanoparticles for treating extracellular bacterial infections
  • Functional Ethionamide boosters: a novel combination for tuberculosis therapy
  • Intravenous treatments of serious infections (urinary tract infections (UTI), intra-abdominal infections (IAI) & hospital-acquired pneumonia/ventilator associated pneumonia (HAP/VAP)) caused by Gram(-) bacteria (Enterobacteriaceae +/- Pseudomonas and/or Acinetobacter)

More information on the topics can be found in IMI’s press release and in the Call text. Other relevant documents can be found on the IMI2 Call documents page.

 

Projects

The projects resulting from IMI2 – Call 16 are:

  • AB-DIRECT - Antibiotic distribution and recovery in tissue
    factsheet | website
  • TRIC-TB - Boosting Ethionamide efficacy and lowering the dose with a small molecule transcriptional modulators, to overcoming MDR-TB infections and define a new place for Ethionamide in 1st-line TB treatments.
    factsheet | website
  • RespiriTB - Progress new assets (one pre-new molecular entity and one first-time-in-human start) for tuberculosis that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors
    factsheet | website
  • RespiriNTM - Progress novel assets (one FIH start) for non-tubercular mycobacteria that may act synergistically with bedaquiline and cytochrome bc drugs
    factsheet | website
  • GNA NOW - Novel Gram-negative antibiotic now
    factsheet | website

 

Call statistics

  • Proposals submitted: 6
  • Inadmissible & ineligible proposals: 0
  • Proposals recommended for funding: 5
  • Proposals not recommended for funding: 1

 

Reports